Merck is increasing its HPV vaccine production capacity, but it still won't be enough to meet the full demand in China, a company spokesperson said.
There aren’t any vaccines against the painful viral infection chikungunya, but with new phase 2 results, Themis is one step closer to changing that.
Here is some other vaccine news of note for the week.
Merck's RotaTeq won China approval in April and a launch is underway, but meanwhile, the company is reducing its shipments to low-income countries.
GlaxoSmithKline's Shingrix is propelling growth at the drugmaker, but tight supply might limit its expansion in the near term.
Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.
The FDA put Sanofi's Dengvaxia, the dengue vaccine at the center of a safety scandal this year in the Philippines, on its priority track for approval.
The Institut Pasteur spinoff hopes its anti-telomerase cancer vaccine could be useful in immuno-oncology combo therapies.
Merck's Gardasil generated $1 billion in Q3, prompting an analyst to wonder just how much the shot might be able to generate in the long run.
